news
Real-world Evidence: Managing Platelet Counts in Ovarian Cancer Patients on First-Line Maintenance Niraparib
A US cohort study of 543 ovarian cancer patients revealed 37% experienced decreased platelets during niraparib maintenance. Onset typically occurred within 1 month but resolved rapidly with dose adjustments, resulting in low discontinuation
